Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Part of paid clinical trials in Columbia, Missouri.

Sponsor
Bo Lu
Study ID
NCT06410300
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Curative Radiotherapy — RADIATION
    Radiation dose of 45 Gy or higher
  • Immunotherapy — DRUG
    checkpoint inhibitor per PI discretion

Study Details

The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.

Key Dates

Start date
Apr 19, 2024
Status verified
Jun 2025
Primary completion
Apr 19, 2028
Completion
Apr 19, 2030

Study Design

Enrollment
125 participants (estimated)

Primary Outcome Measure

Clinical cardiopulmonary toxicities [ Time Frame: 25 months ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
University of Missouri - Ellis Fischel Cancer CenterColumbiaMissouri65212
Bo Lu, MD (PRINCIPAL_INVESTIGATOR)
Gregory Biedermann, MD (SUB_INVESTIGATOR)
Ruobing Xue, MD (SUB_INVESTIGATOR)
Rutgers Cancer Institute of New JerseyNew BrunswickNew Jersey08901
Salma Jabbour, MD (PRINCIPAL_INVESTIGATOR)
University of Rochester Medical CenterRochesterNew York14642
Yuhchyau Chen, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Columbia, MO

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of Missouri - Ellis Fischel Cancer Center· Columbia, MORutgers Cancer Institute of New Jersey· New Brunswick, NJUniversity of Rochester Medical Center· Rochester, NY

Related Studies